Sign In
Buy MBX
$48.40
+2.01 (+4.33%)
At Close: Jun 24, 2026
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
10:43am, Friday, 12'th Jun 2026
MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide i
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
08:00am, Monday, 01'st Jun 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
03:18pm, Wednesday, 27'th May 2026
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
08:00am, Tuesday, 26'th May 2026
CARMEL, Ind. and BURLINGTON, Mass.
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
02:31pm, Thursday, 14'th May 2026
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
08:10pm, Monday, 11'th May 2026
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
03:09pm, Monday, 11'th May 2026
MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key devel
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
08:00am, Thursday, 07'th May 2026
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Ma
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07:00am, Thursday, 07'th May 2026
CARMEL, Ind. and BURLINGTON, Mass.
Microbix Schedules Release of Results for Q2 Fiscal 2026
07:00am, Thursday, 07'th May 2026
Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovat
3 Overlooked Stocks Set to Soar in 2026
08:45am, Tuesday, 05'th May 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Microbix Product Results Being Presented at 2026 PASCV
07:00am, Monday, 27'th Apr 2026
MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its clien
